Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Acupuncture also improves sex drive while reducing hot flashes in breast cancer patients

Not only is acupuncture as effective as drug therapy at reducing hot flashes in breast cancer patients, it has the added benefit of potentially increasing a woman's sex drive and improving her sense of well-being, according to a Henry Ford Hospital study.

30 Dec 2009

Phase 3 trial of figitumumab discontinued by Pfizer

Pfizer Inc. announced today the discontinuation of A4021016 (also known as ADVIGO 1016), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) as first-line treatment in patients with advanced non-adenocarcinoma non-small cell lung cancer (NSCLC) due to the study meeting predefined boundaries for early termination.

30 Dec 2009

Affomix to generate antibodies against proprietary targets chosen by Kalgene

Affomix Corporation, a pioneer in the development of automated, high-throughput monoclonal antibody selection technology, announced today that Kalgene Pharmaceuticals Inc. has signed a commercial agreement to have Affomix utilize its Y2HExpress™ technology to select antibodies with potential diagnostic and therapeutic utility in breast cancer. Kalgene Pharmaceuticals Inc. is a private company focused on the development of oncology therapeutics and companion diagnostics.

29 Dec 2009

Elekta Crawley receives the World Class Manufacturer of the Year 2009 award

Elekta, the world-leading manufacturer of treatment solutions for cancer and brain disorders, has been awarded the prestigious World Class Manufacturing award by The Manufacturer magazine. The award was given in recognition of the quality work produced each year by Elekta manufacturing staff.

From Elekta 29 Dec 2009

Advaxis reports 3-year survival data from its ADXS11-001 Phase I trial for cervical cancer

The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc., the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in two (2) of the thirteen (13) evaluable patients treated with Advaxis’ therapeutic cancer vaccine, indicating the possibility of persistent immune protection, from only a two (2) dose initial regimen.

29 Dec 2009

CGEN-671, a new drug target for multiple epithelial tumors discovered by Compugen

Compugen Ltd. announced today the discovery and experimental validation of CGEN-671, a new drug target for multiple epithelial tumors.

28 Dec 2009

Cell Therapeutics adopts ‘Rights Plan’ to protect shareholder interests

Cell Therapeutics, Inc. (CTI) announced today that on December 24, 2009, CTI's Board of Directors (the "Board of Directors") approved and adopted a Shareholder Rights Plan (the "Rights Plan") in which one preferred stock purchase right will be distributed for each common share held as of the close of business on January 7, 2010. Initially, the rights are not exercisable, and are attached to and trade with, all of the shares of CTI's common stock outstanding as of, and issued subsequent to, the record date.

28 Dec 2009

MDRNA closes $1M bridge loan

MDRNA, Inc., a leading RNAi-based drug discovery and development company, today announced the closing of a bridge loan pursuant to a Note and Warrant Purchase Agreement. Under the terms of the loan, the Company sold promissory notes in the aggregate principal amount of $1.0 million and issued warrants to purchase an aggregate of approximately 1.1 million shares of the Company's common stock at $1.02 per share to certain accredited investors.

24 Dec 2009

Scientists use DNA sequence to characterize genome rearrangement in breast cancer samples

The first detailed search of breast cancer genomes to uncover genomic rearrangements is published today. The team characterised the ways in which the human genome is broken and put back together in 24 cases of breast cancer.

23 Dec 2009

Cold Spring Publishing renamed as Harborside Press

Cold Spring Publishing, LLC, announced today that the principals of the company have approved a name change to Harborside Press, LLC.

23 Dec 2009

Cutting Edge Information: Top five research reports

As business intelligence firm Cutting Edge Information (http://www.cuttingedgeinfo.com) reflects on its accomplishments in 2009, the company pays special tribute to its five best-selling benchmarking research reports of the year by showcasing its top picks to the company's top supporters.

23 Dec 2009

Otsuka America Pharmaceutical joins NPC

The National Pharmaceutical Council (NPC) today announced that Otsuka America Pharmaceutical, Inc. has joined the health policy research organization as a member.

23 Dec 2009

Latest diagnosis and treatment of small and non-small cell lung cancer

Under the auspices of the 12th International Symposium on Special Aspects in Radiotherapy 2008 in Berlin, acknowledged experts presented their perspectives on small and non-small cell lung cancer, reflecting the latest standards and engaging in controversies in the diagnosis and treatment of this disease.

23 Dec 2009

Comprehensive review of cell migration

Cell migration is a highly complex process which involves several compartments of the cell, including surface receptors, signalling elements and the cytoskeleton.

23 Dec 2009

CEO Cancer Gold Standard accreditation for Aldagen

Aldagen, Inc. has received CEO Cancer Gold Standard™ accreditation, recognizing the company’s commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace.

23 Dec 2009

Nationwide Children's Hospital chosen as a BCR for TCGA

Nationwide Children's Hospital recently was awarded an initial $5.5 million contract from the National Cancer Institute (NCI) to serve as a Biospecimen Core Resource (BCR) for The Cancer Genome Atlas (TCGA), a program co-managed by the NCI and the National Human Genome Research Institute (NHGRI), both part of the National Institutes of Health (NIH).

23 Dec 2009

Second successful phrenic nerve decompression surgery

The Plastic Surgery Center today announced that immediately following a rare phrenic nerve surgery to repair his paralyzed diaphragm, a 47-year-old man has reported significantly improved breathing and feels “15 years younger.” The surgery marked the second known case of successful phrenic nerve decompression, both of which were performed by a New Jersey medical team led by Dr. Matthew Kaufman of the Plastic Surgery Center in Shrewsbury, New Jersey.

23 Dec 2009

UPMC reports 10,000th patient treated using Elekta's Leksell Gamma Knife system

On the morning of December 17, 2009, UPMC physicians used Gamma Knife® surgery to treat the center's 10,000th patient, an 81-year-old male with a tumor deep in his brainstem, a site where traditional surgery would have been impossible. Gamma Knife surgery is performed using Elekta's Leksell Gamma Knife system, which directs up to 201 pencil-thin beams of therapeutic radiation precisely on brain tumors and other targets in the head.

From Elekta 23 Dec 2009

US Oncology to host webinar to discover how new legislation will impact cancer care in 2010

Federal legislation on health care reform and coverage expansion will have major impacts on cancer care. Community oncology professionals need to know how this legislation impacts them and their community practice. US Oncology, Inc., supporting the nation's foremost cancer treatment and research network, announced today that it will host a complimentary educational webinar for community-based oncology practices to discover how this new legislation will impact cancer care in 2010.

23 Dec 2009

U.S. Congress approves $1.6 million for AdMeTech Foundation's research program

AdMeTech Foundation, a nonprofit organization, announced today that the U.S. Congress has approved $1.6 million for funding of its groundbreaking research program aimed at developing novel imaging technologies for early prostate cancer detection, which in turn is critical for saving lives and designing customized patient care, including the most effective and the least invasive approach.

23 Dec 2009